<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20141007019432N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-06-10</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Preperation and characterization of lipospmal Epidermal growth factor and evaluating its efficacy on preorbital wrinkles</public_title>
      <acronym>---</acronym>
      <scientific_title>Preparation and characterization of lipospmal Epidermal growth factor and evaluating its efficacy on preorbital wrinkles</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>15</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/30378</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: ------, Randomization description: Randomisation Tool: Plumbed Envelope 
 Two groups A, B are placed in the plumbed envelope. In Group A, the liposomal growth factor production is used on the right side and the left side of the placebo and group  B the right side of the placebo  and the left side of the  Liposomal growth factor production is used, Blinding description: In this  double  blind study , participants  and analyser are unaware of the allocation of study groups.</study_design>
      <phase>1</phase>
      <hc_freetext>Aging and preorbital wrinkle.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:In this study, 15 patients with the same conditions of entry are matched with t skin and stem cells research center . wrinkles around the eye on one of the side face are considered as intervention and the other site as a control. The topical cream application is used for 3 months for twice a day ( morning and night). evaluating the efficacy of the cream, by the biometric factors are examined once before the intervention and then 3 months later. Fallow up is done until the 6th month. Intervention 2: Control group:The control group in this study is the same as participating in intervention, one side of the face being considered as a control.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mohammadamir Amirkhani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Skin  and Stem Cell Research Center in Tehran University of Medical Sciences ,Maryam deadend,sough Kamranieh ,Tehran Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1937957511</zip>
        <telephone>+98 22201710</telephone>
        <email>amirkhani2000@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Masoud Ahmadvand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty Paramedicine ,Iran University,Tehran Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>141556183</zip>
        <telephone>+98 21 8670 4601</telephone>
        <email>d.ahmadvand@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Aged  between 35 to 50 years old.
Having a healthy face  for dermatological, anatomical and sympathetic diseases
Being in the wrinkle grade 2 and 3 according to the Lemperle 4 table
Having psychological and social health (based on self-expression)
Having knowledge And have enough time to cooperate until the end of the plan</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Without any restorative intervention in the form of sub-sission , botox, filler, lift and surgery and etc,
Having plenty of wrinkles in different areas of the skin
Mental and  social  obsessive-compulsive disorder (based on self-declaration)
history of related skin diseases, autoimmune, allergies or inflammation near the site
history of prematurity cardiovascular, respiratory, diabetes, wound healing, moderate to high anemia, and other diseases that affect the process of rejuvenation
history of systemic diseases
history of oral and maxillofacial infections
positive screening tests HIV1.2Ab, HBsAg, HbcAb, HCVAb,</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:In this study, 15 patients with the same conditions of entry are matched with t skin and stem cells research center . wrinkles around the eye on one of the side face are considered as intervention and the other site as a control. The topical cream application is used for 3 months for twice a day ( morning and night). evaluating the efficacy of the cream, by the biometric factors are examined once before the intervention and then 3 months later. Fallow up is done until the 6th month.</i_keyword>
      <i_keyword>Control group:The control group in this study is the same as participating in intervention, one side of the face being considered as a control.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Effect of liposomal epidermal growth factor production  on the surface and depth  of preorbital wrinkle. Timepoint: before intervention and 3 months after using. Method of measurement: The statistical population is according to the degree of wrinkles 2 and 3 in thecase of women aged between 35 and 50 years that are selected by written consent. In this study,  viscosity of the skin with visioface (D1000 ck Cologne, Germany), the level and degree of wrinkle  with the set         (LL 650 CK Germany), the thickness and density of the skin, the dermal and epidermal  with ultrasound skin scanner, DUB-TPA EOTECH, Marcoussis, France), Multiprobe , elasticity  with Adapter Cutometer (Cologne, Germany)  ,skin water levels by chronometer devices  are examined before and after using cream for 3 months and the numbers will be compared. All statistical analyses will be done in SPSS software.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Effect of liposomal epidermal growth factor production  on moisture ,elasticity and dermal -epidermal  thickness,. Timepoint: before intervention and 3 months after using. Method of measurement: The statistical population is according to the degree of wrinkles 2 and 3 in thecase of women aged between 35 and 50 years that are selected by written consent. In this study,  viscosity of the skin with visioface (D1000 ck Cologne, Germany), the level and degree of wrinkle  with the set         (LL 650 CK Germany), the thickness and density of the skin, the dermal and epidermal  with ultrasound skin scanner, DUB-TPA EOTECH, Marcoussis, France), Multiprobe , elasticity  with Adapter Cutometer (Cologne, Germany)  ,skin water levels by chronometer devices  are examined before and after using cream for 3 months and the numbers will be compared. All statistical analyses will be done in SPSS software.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-01-10</approval_date>
        <contact_name>Tehran  University of Medical Sciences</contact_name>
        <contact_address>Tehran University of Medical Sciences Cross Qods st , Keshavarz Blvd, Tehran ,Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
